Page 4 - தேசிய நிறுவனம் க்கு கண்டுபிடிப்பு News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Military Service Members Earn Biomanufacturing Certification through New Initiative | North Carolina Biotechnology Center
ncbiotech.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from ncbiotech.org Daily Mail and Mail on Sunday newspapers.
Diese Unternehmen sind Innovations-Champions / Studie untersucht Innovationskraft der 7 000 größten Firmen Deutschlands
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Summary of White House Supply Chain Review | McGuireWoods Consulting
jdsupra.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from jdsupra.com Daily Mail and Mail on Sunday newspapers.
Training for success
New biopharmaceutical sciences masterâs program launches with industry support
Fueled by generous philanthropic support and insights from industry partners, the University of Delaware launched a new masterâs program in biopharmaceutical sciences in June.
AstraZeneca, Bristol Myers Squibb and Merck & Co. contributed leadership support to lay the foundation for the program and will provide the first cohort of students with funding, extended internships and mentorship. In addition to the philanthropic gifts which will help create equity and access for students of underrepresented groups, executives from the companies helped shape the vision and program experience. Their input and expertise ensure students are gaining valuable knowledge and experiences that will enable them to contribute more quickly and meaningfully once they join the industry workforce after graduation.
Biotechnology Company Centivax Officially Launches
News provided by
Share this article
Share this article
SAN FRANCISCO, April 29, 2021 /PRNewswire/ Centivax Inc. is proud to announce its launch on Jan. 1, 2021, as a fully independent biotechnology company developing broad-spectrum therapeutics and a vaccines portfolio, including indications in COVID-19, multi-drug resistant bacteria, influenza, antivenom and oncology. Our unusually mature portfolio of fully owned Centivax assets has been made possible by advanced computational immunoengineering technology platforms and intellectual property that enable Centivax to rapidly create the broad-spectrum antibodies and broad-spectrum vaccines clearly needed in 21st-century medicine, says Dr. Jacob Glanville, Founder and CEO of Centivax. It is these platforms that enable Centivax to enter clinical development of our first therapeutic within eight months of launch.